Aid in diagnosis of contactin associated protein 2 (CASPR2) antibody disorders associated with acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Use to manage antibody-positive (CASPR2) individual following immunotherapy and/or plasmapheresis. Serum is the preferred specimen; see Contactin-Associated Protein-2 Antibody, IgG with Reflex to Titer, Serum (2009452).
Semi-Quantitative Indirect Fluorescent Antibody
New York DOH Approval Status
Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Contaminated, hemolyzed, or severely lipemic specimens.
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month
Less than 1:1
Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.
The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Tumors such as thymoma, small cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.
This indirect fluorescent antibody assay utilizes contactin-associated protein-2 (CASPR2) transfected cell lines for the detection and semi-quantification of the CASPR2 IgG antibody.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
If CASPR2 antibody IgG is positive, then CASPR2 antibody IgG titer will be added. Additional charges apply.
86255; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|3001987||CASPR2 Ab IgG Screen by IFA, CSF||90820-2|